6IV Stock Overview
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Inventiva S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €3.16 |
52 Week High | €4.34 |
52 Week Low | €2.20 |
Beta | 0.98 |
1 Month Change | -10.75% |
3 Month Change | -0.16% |
1 Year Change | 32.84% |
3 Year Change | -73.03% |
5 Year Change | n/a |
Change since IPO | -73.31% |
Recent News & Updates
Recent updates
Shareholder Returns
6IV | DE Biotechs | DE Market | |
---|---|---|---|
7D | 6.8% | -2.2% | 2.5% |
1Y | 32.8% | -25.2% | 6.0% |
Return vs Industry: 6IV exceeded the German Biotechs industry which returned -21.2% over the past year.
Return vs Market: 6IV exceeded the German Market which returned 5.4% over the past year.
Price Volatility
6IV volatility | |
---|---|
6IV Average Weekly Movement | 10.3% |
Biotechs Industry Average Movement | 5.2% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6IV has not had significant price volatility in the past 3 months.
Volatility Over Time: 6IV's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 122 | Frederic Cren | www.inventivapharma.com |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Inventiva S.A. Fundamentals Summary
6IV fundamental statistics | |
---|---|
Market cap | €169.55m |
Earnings (TTM) | -€110.43m |
Revenue (TTM) | €23.16m |
7.3x
P/S Ratio-1.5x
P/E RatioIs 6IV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6IV income statement (TTM) | |
---|---|
Revenue | €23.16m |
Cost of Revenue | €1.02m |
Gross Profit | €22.15m |
Other Expenses | €132.57m |
Earnings | -€110.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 25, 2024
Earnings per share (EPS) | -2.12 |
Gross Margin | 95.61% |
Net Profit Margin | -476.73% |
Debt/Equity Ratio | -148.3% |
How did 6IV perform over the long term?
See historical performance and comparison